Multifocal Motor Neuropathy

Neurology
2
Pipeline Programs
2
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

argenx
argenxBelgium - Zwijnaarde
2 programs
1
ARGX-117Phase 21 trial
A Prospective Longitudinal Study in Adults With Multifocal Motor NeuropathyN/A1 trial
Active Trials
NCT05988073Active Not Recruiting413Est. Dec 2028
NCT05225675Completed54Est. Jun 2024
DT
1 program
1
DNTH103Phase 21 trial
Active Trials
NCT06537999RecruitingEst. Mar 2028

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
Dianthus TherapeuticsDNTH103
argenxARGX-117
argenxA Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Clinical Trials (3)

Total enrollment: 467 patients across 3 trials

A Clinical Study to Evaluate DNTH103 in Adults With Multifocal Motor Neuropathy

Start: Sep 2024Est. completion: Mar 2028
Phase 2Recruiting

A Clinical Trial to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, Pharmacodynamics and Immunogenicity of 2 Dose Regimens of ARGX-117 in Adults with Multifocal Motor Neuropathy

Start: Mar 2022Est. completion: Jun 202454 patients
Phase 2Completed
NCT05988073argenxA Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

A Prospective Longitudinal Study in Adults With Multifocal Motor Neuropathy

Start: Nov 2023Est. completion: Dec 2028413 patients
N/AActive Not Recruiting

Related Jobs in Neurology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 467 patients
2 companies competing in this space